Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Trospium Chloride (Sanctura XR®)
Trospium Chloride · 1 trial · 1 indication
Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.
| Arm | Type | Description |
|---|---|---|
| Glucophage® then Sanctura XR® (AB) | EXPERIMENTAL | Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days. |
| Sanctura XR® then Glucophage® (BA) | EXPERIMENTAL | Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days. |
| Name | Type | Description |
|---|---|---|
| Trospium Chloride (Sanctura XR®) | DRUG | extended release, 60 mg, oral daily |
| Metformin hydrochloride (Glucophage®) | DRUG | immediate release, 500mg |
Inclusion Criteria: * Weight within +/-30% of ideal body weight for height and frame size * Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 1 months prior to the screening visit). * Willing to abstain from caffeine-containing food and beverages...
Trospium chloride is a small molecule drug developed by AbbVie Inc. (ticker ABBV). It is an antagonist of the CHRM2 and CHRM3 muscarinic acetylcholine receptors. The compound is also known by the brand name Sanctura XR. Its clinical development has included Phase 1 study in healthy volunteers.
Trospium chloride targets CHRM2 and CHRM3, two muscarinic acetylcholine receptor subtypes. It acts as an antagonist at these receptors, meaning it blocks receptor activity. This target profile places trospium chloride in the antimuscarinic class of small molecule therapeutics.
Trospium chloride is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company associated with the clinical development program for the drug, including the Phase 1 study conducted in the United States.
Trospium chloride is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study was a randomized, controlled Phase 1 trial in healthy subjects.
Trospium chloride has been studied in trial NCT00986401, titled Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects. This completed Phase 1 trial enrolled 44 participants in the United States, included both sexes, and required participants to be at least 18 years old.
Yes, trospium chloride is also known as Sanctura XR. Sanctura XR is a brand name for trospium chloride, so searches for either name refer to the same drug developed by AbbVie Inc. under ticker ABBV.